Keratoconus Treatment Market Analysis

In-depth Analysis of Keratoconus Treatment Market Industry Landscape

The increase in ultraviolet (UV) exposure is considered a significant factor in the development of keratoconus, a condition characterized by the thinning of the cornea due to oxidative damage. This is particularly evident in regions with high temperatures and abundant sunlight. The theory suggests that UV light triggers the overproduction of reactive oxygen species in the cornea. In individuals with keratoconus, the cornea struggles to handle this excess, leading to oxidative stress, cytotoxicity, and the thinning of the cornea. Countries like Saudi Arabia, Iran, New Zealand, Israel, and certain Pacific Islands, where UV exposure is high, have shown a higher prevalence of keratoconus.

The escalating levels of ultraviolet and sun exposure contribute to the increased occurrence of keratoconus, thereby driving the demand for keratoconus treatment. This trend also provides motivation for companies to invest in the development of new therapeutic approaches and advanced treatment methods.

Government support plays a crucial role in addressing ophthalmic disorders such as keratoconus. In both developed and some developing countries, various government and private organizations actively contribute to research and prevention programs for eye conditions. Researchers have introduced innovative products for diagnosing and treating eye diseases, presenting substantial market potential. For instance, in 2016, the Eye Health Examinations Wales (EHEW) scheme conducted approximately 121,736 eye examinations, according to the United Kingdom Statistics Authority. Additionally, the Eye Defects Research Foundation receives government support for its work on keratoconus research.

Government funding has significantly impacted the affordability and accessibility of keratoconus treatments. Nexus Hospitals, for example, announced Medicare funding for corneal cross-linking in the treatment of keratoconus, incorporated into the Medicare Benefits Scheme starting May 1, 2018. This move has made the procedure more affordable for patients. With improved community access to the primary treatment for progressive keratoconus, better visual outcomes can be expected, potentially reducing the need for more invasive treatments like corneal transplantation.

The growing support from governments, manifested through adequate funding for eye care, is poised to stimulate the market's growth. As a result, research and development efforts are likely to intensify, leading to more effective treatments and diagnostic tools for keratoconus. The positive impact of government initiatives not only enhances the overall quality of eye care but also contributes to advancements in the field of ophthalmology, ultimately benefiting individuals affected by keratoconus.